Page 2 - Chris Senner News Today

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders (the “Annual...

Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Vaishnavi, and Ill be your operator for today.

EXEL earnings call for the period ending December 31, 2022.

- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 -- Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 -- GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2...

EXEL earnings call for the period ending June 30, 2022.

Blessey Marine Services christened the 2,600 hp. retractable-pilothouse towboat Walter E. Blessey, Jr., built by Vessel Repair.

Exelixis, Inc. (NASDAQ:NASDAQ:EXEL) Q1 2022 Earnings Conference Call May 10, 2022, 05:00 PM ET Company Participants Susan Hubbard - EVP of Public Affairs and IR Mike Morrissey - President...

EXEL earnings call for the period ending March 31, 2022.

EXEL earnings call for the period ending December 31, 2021.

— Corporate priorities for 2022 include initial readout of up to three cabozantinib pivotal trials; initiation of pivotal trial program for XL092; expansion of clinical programs for XL092, XB002 and XL102; and multiple new development candidates from small molecule and biologics programs —— Cabozantinib franchise ac...